A new oral dosage form of olaparib (Lynparza) has been approved as maintenance treatment in women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.
Researchers from the United States, Netherlands, and Denmark have collaborated on developing a new liquid biopsy test that can detect circulating cell-free DNA in patients with early-stage cancer.
A new study, published in the journal Nature, has confirmed the efficacy of a melanoma vaccine targeted against 20 predicted personal tumor neoantigens in 6 patients.
A retrospective study in patients with newly diagnosed cancer has identified an increased risk of cardiovascular (CV) abnormalities that are aggravated by cancer stage.
Patient reported data can be a reliable source of information to ascertain comorbidities in patients with prostate cancer, says JAMA Oncology study.
A study in JAMA Oncology has found that unpreparedness for treatment-related expenses among patients being treated for cancer can bear upon the patient’s future decision-making.
Syapse improves patient outcomes by providing workflow solutions that enable cancer care providers to deliver precision medicine within their organization, Ken Tarkoff, the company's CEO, told Evidence-Based Oncologyâ„¢.
The Institute for Clinical and Economic Review (ICER) has released a draft version of their scoping document that will compare the clinical effectiveness and value of 2 chimeric antigen receptor (CAR)-T cell treatments being reviewed by the FDA.
Will right-to-try improve patient access to investigational drugs?
New research has found that the steady increase in the price of targeted oral anticancer medications is washing out the potential for savings that patients would experience in their out-of-pocket payments following closure of the Medicare Part D coverage gap.
There’s a lot happening in clinical practice with immunotherapy treatments: expanded indications for nivolumab and ipilimumab, biomarkers to judge patient response to combinations, and developments with CAR-T.
Provider roles in team-based care in oncology need clarity, and now, results from a new study affirm the confusion experience by patients treated for breast cancer on who should lead their care posttreatment.
The approval follows a review of phase 2 results from CheckMate-142.
Enasidenib (Idhifa), developed by Celgene and Agios, has been granted FDA approval in tandem with a companion diagnostic test to detect IDH-2 mutations.
The FDA has announced a regulatory plan that could shift the trajectory on tobacco-related disease and death.
A new study has analyzed data from randomized controlled trials in oncology that used surrogate endpoints and measured their relation with treatment effectiveness and patient survival in the real world.
Patient refusal, symptom burden, and diagnostic disparities were identified as some of the most common barriers encountered when recruiting patients with advanced cancer for palliative treatment in the emergency department (ED).
In a study presented at the 2017 American Society of Clinical Oncology Annual Meeting, researchers at MD Anderson Cancer Center used data on 12,052 elderly patients diagnosed with neuroendocrine tumors to analyze their resource utilization.
In a study presented at the 2017 American Society of Clinical Oncology Annual Metting, researchers from the Brazilian Cancer Foundation and the Brazilian National Cancer Institute evaluated the cost-effectiveness of a unique exam using next-generation sequencing versus other routine tests.
Including adjuvant chemotherapy in the postsurgical treatment plan in patients with non—small cell lung cancer (NSCLC) improves survival and is cost-effective compared with surgical resection alone, according to analysis results presented at the 2017 American Society of Clinical Oncology Annual Meeting.
A discussion at the 2017 American Society of Clinical Oncology Annual Meeting addressed practical solutions to address the financial toxicity of cancer care and identified leads for future intervention studies aimed to prevent or reduce this burden.
After switching studies, research in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy has found clinical equivalence between filgrastim and its biosimilar, according to results presented at the 2017 Annual Meeting of the American Society of Clinical Oncology.
A poster discussion session at the 2017 Annual Meeting of the American Society of Clinical Oncology led by Katherine Van Loon, MD, MPH, examined retrospective surveillance data in 3 cancers: non—small cell lung cancer, head and neck cancer, and colorectal cancer.
At the 2017 American Society of Clinical Oncology Annual Meeting, oncologists heard from fellow experts on the best way to navigate the daunting challenge of payment reform.
A kickoff session on the first day of the 2017 American Society of Clinical Oncology Annual Meeting in Chicago turned in to a lively discussion on ensuring that the data used to inform patient care and create healthcare policies hold value, which could entail foraging real-world data captured in health records.
Researchers at the University of Pennsylvania have recognized that narrow provider networks are quite likely to exclude National Cancer Institute—Designated Cancer Centers or National Comprehensive Cancer Network Cancer Centers, which could prevent patient access to high-quality cancer care.
Results from a collaborative study across the United States indicate that patients with colon cancer who had a healthy body weight, engaged in physical activity, and ate a healthy diet had longer survival.
The incidence of human papilloma virus (HPV)-positive oropharyngeal cancer can be reduced with a prophylactic vaccine, according to a collaborative study that was presented at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago.
Researchers at the Beth Israel Deaconess Medical Center in Boston investigated the impact of patient engagement in evaluating their care visit notes and found patients and care partners who chose to provide feedback were enthusiastic about assisting with improving the accuracy of clinician notes.
According to findings from a 63-center international study, published in the New England Journal of Medicine, complete lymph node excision may not be essential for improved outcomes in melanoma.